Mounjaro Tirzepatide 12.5mg Injections - An Overview
The trial attained both equally its Most important endpoints, with semaglutide 2.four mg demonstrating statistically substantial and excellent improvements in liver fibrosis with no worsening of steatohepatitis, and resolution of steatohepatitis with no worsening of liver fibrosis in people with MASH when compared with placebo.oneAssuming the above